JNJ-79635322 + daratumumab + lenalidomide

JNJ-79635322 + daratumumab + lenalidomide is a combination regimen involving a novel agent (JNJ-79635322) together with **daratumumab**, a CD38-targeting monoclonal antibody, and **lenalidomide**, an immunomodulatory drug. Daratumumab induces tumor cell death by antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity; lenalidomide modulates immune response and has anti-neoplastic activity. JNJ-79635322 is under investigation and specific details about its mechanism are not publicly established, but as an investigational Janssen compound, it is likely targeted at novel molecular pathways in multiple myeloma. This combination is being studied for relapsed or refractory multiple myeloma, aiming to deepen response and prolong survival by integrating complementary immunotherapies and molecular modulation.